Date: 2016-12-02
Type of information: Company acquisition
Acquired company: Acetylon Pharmaceuticals (USA - MA)
Acquiring company: Celgene (USA - NJ)
Amount: undisclosed
Terms: * On December 2, 2016, Acetylon Pharmaceuticals announced that it has entered into an agreement to be acquired by Celgene. Financial terms of the acquisition are not being disclosed. The transaction is subject to customary closing conditions, including the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. BMO Capital Markets Corp. served as exclusive financial advisor to
Acetylon in the transaction.
Details: The acquisition will provide Celgene with, among other things, worldwide rights to Acetylon’s selective HDAC6 inhibitor programs and intellectual property in oncology, neurodegeneration, and autoimmune diseases, including its lead drug candidates citarinostat (ACY-241) and ricolinostat (ACY-1215).
Related: Cancer - Oncology Autoimmune diseases
